News|Articles|January 22, 2025
Identify Optimal Biologic Candidates: Low Volume, Early Stage Developability Assessment with Aura PTx
Author(s)Halo Labs
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy
2
Next-Generation Modalities Drive New Antibody Discovery
3
Green Chemistry’s Role in Advancing US Chemical Innovation
4
Industry Outlook 2026: Biopharma Industry Confronts Skills Shortage with Strategic Automation (Part 2)
5